Novartis AG (LTS:0K9E)
$ 104.7 0 (0%) Market Cap: 209.81 Bil Enterprise Value: 227.95 Bil PE Ratio: 12.53 PB Ratio: 5.07 GF Score: 80/100

Novartis AG at Novartis Co-Creating Impact Summit (Virtual) - Morning Session Transcript

Dec 02, 2021 / 07:00AM GMT
Release Date Price: $75.12 (-0.77%)
Lutz Hegemann
Novartis AG - Group Head of Corporate Affairs & Global Health

(technical difficulty)

social and governance considerations into our core business because we believe that taking ESG at the heart of our business helps reduce risk, it drives value and impact. And fundamentally, it's the right thing to do for humanity. We believe that it starts with a very clear purpose, which we have defined together with our associates and with external stakeholders, and we see our mandates to innovate with new medicines and to make them available to as many patients as possible. And we have validated this also as an external expectation from stakeholders over and over again, for instance, through our materiality analysis where we just completed the most recent analysis a few months ago and which I'm sure will be subject of discussion throughout the day.

While articulating this intent of ESG business integration, it's relatively easy to do, doing it is certainly hard work and very continuous efforts. And here at Novartis, we certainly don't claim [this] on a learning journey, trying new

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot